OPKO HEALTH, INC.
OPKO Health is a diversified healthcare company with pharmaceutical and diagnostics segments. Its pharmaceutical business sells Rayaldee, an oral treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency, and develops therapies for cancer, infectious diseases, metabolic disorders and other conditions. NGENLA, a once-weekly human growth hormone injection, is commercialized globally by Pfizer; OPKO receives a regional, tiered gross profit share. Its pharmaceutical operations include platforms in Spain, Ireland, Chile and Mexico, and EirGen in Ireland develops and supplies high-potency oral solid-dose medicines. OPKO’s diagnostics segment primarily comprises BioReference, which provides laboratory testing to healthcare providers and other customers. Its operations include clinical and women’s health testing in New York and New Jersey, national urology testing through the 4Kscore prostate cancer test, and correctional healthcare services. OPKO is headquartered in Miami, Florida.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $OPK in the last 30 days.
See all $OPK insider activity →Opko Health (OPK) reported Q3 EPS of -$0.07, matching estimates, but revenue of $65.4M fell short of the $136.62M consensus. The stock is up 29.2% over the last 3 months and 32.1% over the last 12 months. InvestingPro rates the company's financial health as 'good performance'.
OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Results of Operations and Financial Condition. OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results Conference Call to Begin Today at 4:30 p.m. ET MIAMI, November 4, 2026 – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial re
OPKO Health (NASDAQ: OPK) announced a $722M deal with Labcorp for its diagnostic business, subject to adjustments. Q3 revenue rose 16% to $65.4M, with net loss narrowing to $35.5M. OPKO also secured $125M financing and advanced clinical trials for OPK-8801001 and other drugs.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning OPK (OPKO HEALTH, INC.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 4 bearish.
Recent OPK coverage spans mergers & acquisitions, earnings and financial news.
Revenue miss suggests short-term downside pressure.
The cash proceeds and improved royalty revenue are likely to lift the stock, while the loss of diagnostic operations may offset some upside.
Potential share price decline as the business segment is divested.
Negative pressure as Opko divests a key asset and narrows focus to biopharma.
First‑in‑human dosing could lift the stock if early data are positive.
AlphAI scores every news story that mentions OPK with an AI model for sentiment and relevance, and aggregates insider trades from OPKO HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Opko Health (OPK) reported Q3 EPS of -$0.07, matching estimates, but revenue of $65.4M fell short of the $136.62M consensus. The stock is up 29.2% over the last 3 months and 32.1% over the last 12 months. InvestingPro rates the company's financial health as 'good performance'.
OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Results of Operations and Financial Condition. OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results Conference Call to Begin Today at 4:30 p.m. ET MIAMI, November 4, 2026 – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial re
OPKO Health (NASDAQ: OPK) announced a $722M deal with Labcorp for its diagnostic business, subject to adjustments. Q3 revenue rose 16% to $65.4M, with net loss narrowing to $35.5M. OPKO also secured $125M financing and advanced clinical trials for OPK-8801001 and other drugs.
Labcorp announced acquisitions totaling over $1 billion, including BioReference Health for up to $872 million and Myriad Genetics' Prenatal Health business for $210 million. The deals are expected to add $410 million in first-year revenue. Labcorp aims to expand diagnostic services, while Opko Health will focus on biopharmaceuticals.
OPKO Biologics, a unit of OPKO Health (OPK), dosed the first patient in a Phase 1/2a trial for OPK-8801001, a long-acting drug for acromegaly. The trial will assess safety, tolerability, and pharmacodynamics. Preclinical studies showed dose-dependent suppression of IGF-1, a marker of acromegaly activity.
OPKO Health (OPK) agreed to sell select BioReference Health assets to Labcorp for $722M+ in cash, with a potential $150M earnout. The deal, subject to regulatory approval, includes clinical and women's health testing services and over 80 patient service centers. According to OPKO, the price may adjust based on closing revenues.
Piper Sandler maintained an Overweight rating on OPKO Health, raising its price target to $4.00, a 148.4% upside from the Oct 15 close. The firm cited OPKO's $722M sale of BioReference to LabCorp, which will boost cash reserves to $1.15B, improving financial flexibility and shareholder value.
Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.
OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement . On October 14, 2026, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Hol
Tel Aviv indices saw mixed performance. The Tel Aviv 35 Index fell 0.15%, while the BlueTech Global Index rose 0.21%. Tower Semiconductor dropped 7.61%, and Opko Health surged 26.64% after announcing a $722M asset sale. Electra Real Estate rose 25.30% following a NIS 95M injection.
